Aveanna Healthcare beats expectations again. AVAH reported Q1 2026 earnings of $0.18 per share, crushing estimates by 38.5% and delivering net income of $41.7 million, nearly eight times year-ago results. The stock surged 14% post-earnings. This marks the ninth consecutive quarter of earnings beats and fourteenth straight revenue beat, demonstrating consistent execution. The company raised full-year 2026 guidance, reflecting confidence in its home health and pediatric care expansion strategy. Trading at a forward PE of 11.4 and PEG ratio of 0.77, AVAH appears undervalued relative to growth prospects. Risks include elevated debt levels and negative free cash flow in Q1, plus insider selling activity. However, improving profitability and market position support continued upside potential for investors seeking healthcare exposure with proven operational momentum.
Post from MarketNews_en
Log in to interact with content.